Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Amgen banks on speed to maintain edge in two hot cancer spaces

Amgen’s clinical development strategy aims to make the most of its head start in bispecifics, KRAS

Lauren Martz, Senior Editor
February 27, 2020 11:27 PM UTC
Updated on Feb 28, 2020 at 10:33 PM UTC

Amgen has a first-mover advantage in two of the hottest areas of cancer R&D -- K-Ras and bispecific antibodies. To stay ahead, it’s banking on a combination of rapid clinical development and moving to earlier disease settings.

EVP of R&D David Reese positions the company as an early player in immuno-oncology, largely on the basis of its strategy to choose spots carefully and build a niche...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

BCIQ Target Profiles

K-Ras (KRAS)